beat top bottom line product
gener perform estim eylea dupix
drove major upsid await guidanc
restructur detail expect believ could
ep beat total revenu ahead driven eylea
libtayo dupix note management previous
pre-announc eylea revenu earli januari guidanc remain
conting renegoti sanofi collabor management continu
target management reiter expect new agreement
accret previous estim could accret management
yet offer guidanc indic comfort
takeaway call eylea management reiter see
signific growth opportun come penetr diabet
eye diseas market growth rate associ diabet eye diseas
exce wamd revenu broken indic approxim
wamd diabet eye diseas retin vein occlus management
stagger launch pre-fil syring start mid-decemb
expect full market suppli march management note
materi stock benefit management plan present panorama data
test eylea nonprolif diabet retinopathi angiogenesi meet
phiii trial test high-dos eylea dme expect start mid-
phiii wamd dupix management report total
prescript grew compar weekli new-to-brand
prescript per week management believ captur
adult atop dermat market management note adolesc
market adult market management note elig asthma
opportun pdufa date dupix pediatr atop dermat yoa
phii/iii trial eosinophil esophag on-going phii
part studi expect readout libtayo pivot
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
combin studi nsclc enrol management expect studi
fulli enrol potenti pivot studi basal cell
carcinoma skin expect readout bispecif management
believ bispecif could efficaci monotherapi solid tumor
also test combin management plan initi potenti pivot
monotherapi studi r/r fl r/r dlbcl other management also
plan initi combin studi earlier line non-hodgkin lymphoma
 first patient enrol initi costimulatori bispecif trial test
combin lybtayo advanc prostat cancer
management note costimulatori bispecif local engag t-cell avoid
potenti system safeti issu includ cytokin storm pozelimab management
encourag initi efficaci data plan initi potenti pivot
monotherapi combin sirna trial later year management
previous develop antibodi mer epidem similar
current novel coronaviru antibodi readi test
human month
await guidanc restructur detail remain focus eylea
growth trajectori start face competit novarti beovu
near-term full restructur agreement guidanc
import driver stock would expect investor react posit
final agreement assum management disciplin cost control howev key
clinic catalyst libtayo nsclc interim analysi updat result
trial phiii ngf data repres
import event
eylea dupix oncolog pipelin drive risk-reward
deriv pt discount analysi use wacc
termin growth rate
ew regeneron believ
potenti upsid factor success
libtayo nsclc earli stage
bi-spec pipelin off-set potenti
risk intern refer price
pressur eylea
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
feb gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
strong dupix growth success
strong dupix growth success
oncolog pipelin limit eylea
oncolog pipelin limit eylea
competit biosimilar brand
competit biosimilar brand
competit assum us
eylea row eylea
sarilumab us sale
us dupilumab sale
dupix growth multipl indic
dupix growth multipl indic
us eylea row eylea
us dupilumab sale
eylea pressur limit dupix growth
eylea pressur limit dupix growth
outsid core indic assum
outsid core indic assum
us eylea row eylea
us praluent
modest row praluent sale
dupilumab sale
phii data test pozelimab pnh
updat result r/r fl dlbcl car-t
nave post-car-t
report dose escal interim data phi
trial r/r multipl myeloma
garetosmab submit patient fibrodysplasia
initi phii trial gener lipodystrophi
driver includ impact potenti eylea
competit updat dataset
oncolog pipelin growth dupix
view explan region hierarchi
research highest favor quintil
signic implement part
signic eylea competit sale
signic penetr libtayo nsclc
eylea face brand biosimilar competit
take signic share
oncolog pipelin fail perform
dupix atten earlier expect
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
